ES2106732T3 - Desazaguaninas substituidas en 9 y no substituidas en 8. - Google Patents

Desazaguaninas substituidas en 9 y no substituidas en 8.

Info

Publication number
ES2106732T3
ES2106732T3 ES90906624T ES90906624T ES2106732T3 ES 2106732 T3 ES2106732 T3 ES 2106732T3 ES 90906624 T ES90906624 T ES 90906624T ES 90906624 T ES90906624 T ES 90906624T ES 2106732 T3 ES2106732 T3 ES 2106732T3
Authority
ES
Spain
Prior art keywords
substituted
alkyl
trifluoromethyl
image
represents hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90906624T
Other languages
English (en)
Inventor
John A Secrist Iii
Mark David Erion
John A Montgomery
Steven E Ealick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2106732T3 publication Critical patent/ES2106732T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA ESPECIFICACION DESCRIBE LOS COMPUESTOS DE FORMULA (I), EN LA QUE (A)-CH2
ES90906624T 1989-02-27 1990-02-27 Desazaguaninas substituidas en 9 y no substituidas en 8. Expired - Lifetime ES2106732T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31606389A 1989-02-27 1989-02-27

Publications (1)

Publication Number Publication Date
ES2106732T3 true ES2106732T3 (es) 1997-11-16

Family

ID=23227309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90906624T Expired - Lifetime ES2106732T3 (es) 1989-02-27 1990-02-27 Desazaguaninas substituidas en 9 y no substituidas en 8.

Country Status (15)

Country Link
US (2) US5565463A (es)
EP (1) EP0460116B1 (es)
JP (1) JP2760364B2 (es)
KR (1) KR100208315B1 (es)
AT (1) ATE157363T1 (es)
AU (1) AU640649B2 (es)
CA (1) CA2047216C (es)
DE (1) DE69031337T2 (es)
DK (1) DK0460116T3 (es)
ES (1) ES2106732T3 (es)
FI (1) FI95259C (es)
HU (1) HU217870B (es)
NO (1) NO180049C (es)
RU (1) RU2093513C1 (es)
WO (1) WO1990010631A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072123C (en) * 1989-10-31 2001-06-12 John A. Secrist, Iii Inhibitors of purine nucleoside phosphorylase
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
AU6855594A (en) 1993-06-30 1995-01-24 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
US5650511A (en) * 1995-12-12 1997-07-22 Biocryst Pharmaceuticals, Inc. Process for the preparation of 9-deazaguanine derivatives
CN1107068C (zh) * 1997-05-29 2003-04-30 诺瓦提斯公司 2－氨基－7－(1－取代的－2－羟乙基)－3,5－二氢－吡咯并[3,2－d]嘧啶－4－酮
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
HK1041483B (zh) * 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 雙環氮雜環
EP1382607B1 (en) * 1998-12-31 2009-08-19 Ipsen Pharma Prenyl transferase inhibitors
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
UA104579C2 (uk) 2007-12-10 2014-02-25 Байокрист Фармасьютикалз, Инк. Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
US9616129B2 (en) 2013-06-22 2017-04-11 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
GB202218782D0 (en) 2022-12-13 2023-01-25 Mehrling Thomas Purine nucleoside phosphorylase inhibitor for metabolic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
CA1293727C (en) * 1986-08-26 1991-12-31 Catherine Rose Kostlan 9-deazaguanines
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
EP0374096B1 (de) * 1988-12-14 1992-12-02 Ciba-Geigy Ag 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür

Also Published As

Publication number Publication date
US5721240A (en) 1998-02-24
WO1990010631A1 (en) 1990-09-20
RU2093513C1 (ru) 1997-10-20
HUT58737A (en) 1992-03-30
NO180049C (no) 1997-02-05
EP0460116A4 (en) 1992-05-13
CA2047216A1 (en) 1990-08-28
US5565463A (en) 1996-10-15
EP0460116A1 (en) 1991-12-11
DK0460116T3 (da) 1998-03-30
EP0460116B1 (en) 1997-08-27
AU640649B2 (en) 1993-09-02
HU217870B (hu) 2000-04-28
FI914015A0 (fi) 1991-08-26
ATE157363T1 (de) 1997-09-15
KR100208315B1 (ko) 1999-07-15
DE69031337D1 (de) 1997-10-02
KR920701209A (ko) 1992-08-11
NO180049B (no) 1996-10-28
FI95259B (fi) 1995-09-29
NO913332L (no) 1991-08-26
AU5524890A (en) 1990-10-09
DE69031337T2 (de) 1998-03-05
JPH04503675A (ja) 1992-07-02
CA2047216C (en) 1999-03-30
NO913332D0 (no) 1991-08-26
FI95259C (fi) 1996-01-10
JP2760364B2 (ja) 1998-05-28

Similar Documents

Publication Publication Date Title
ES2106732T3 (es) Desazaguaninas substituidas en 9 y no substituidas en 8.
NO308656B1 (no) Aryltioforbindelser
MX9203687A (es) Nuevos derivados de 6&-metilprednisolona, su obtencion y uso.
SE8405924L (sv) Nya azoforeningar
ZA876094B (en) Carboxamides
ATE13429T1 (de) Neue benzofuran-derivate, ihre herstellung und verwendung.
SE8500107D0 (sv) Neue 8alfa-acylaminoergoline
DK691287A (da) 5-floururacilderivater
NO923226D0 (no) Nytt beta-fenylisoserinderivat, dets fremstilling og anvendelse
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.
ES2067780T3 (es) 2'-desoxi-2'-metilidenocitidina dihidrato, metodos para su produccion y composiciones.
ZA827974B (en) Novel 4-aroylimidazolidin-2-ones
SE7909032L (sv) Peptidderivat
IL62226A (en) ((substituted pyrimidinyl-ureido)-(2,3-dihydro-2-imino-4-thiazolyl))acetamido-cephalosporins,their preparation and pharmaceutical compositions containing them
MY116824A (en) Antivaral,highly water soluble,stable,crystalline salts of 2'',3''-dideoxyinosine monohydrate,2'',3''-dideoxy-2'' ,3''-didehydrothymidine monohydrate and 2'',3''-dideoxy-2''-fluoroinosine hemihydrate
NZ196858A (en) 4-hydroxy- or 4,6-dihydroxy-1,2-benzoisothiazol-3 (2h)-one-1,1-dioxides
GR3004911T3 (es)
FI882824L (fi) Nya heterocykliska foereningar och deras framstaellning.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 460116

Country of ref document: ES